Abstract
Lentiviral vectors are vectors of choice for many gene therapy applications. Recently, efficient targeting of lentiviral vectors pseudotyped with the Measles virus (MV) glycoproteins has been reported. However, MV antibodies in patients might limit the clinical use of these vectors. We demonstrate here that lentiviral vectors can also be pseudotyped with the glycoproteins of Tupaia paramyxovirus (TPMV), the hemagglutinin (H) and fusion (F) protein. As this animal paramyxovirus has no known close relatives in humans, we do not expect TPMV antibodies in patients. Because TPMV normally does not infect human cells, ‘detargeting’ from natural receptors is unnecessary. Similar to the MV system, TPMV glycoproteins can mediate targeted cell entry by displaying different single-chain antibodies (scAb) directed against surface molecules on target cells on the viral hemagglutinin. We generated a panel of H and F proteins with truncated cytoplasmic tails and determined the variants that efficiently pseudotyped lentiviral vectors. The B-cell marker CD20 was used as a model antigen, and CD20-targeted TPMV vectors selectively transduced CD20-positive cells, including quiescent primary human B-cells. Lentiviral vectors pseudotyped with targeted TPMV envelope proteins might be a valuable vector choice when systemic application of targeted lentiviral vectors in humans is required.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
£169.00 per year
only £28.17 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Verma IM, Weitzman MD . Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005; 74: 711–738.
Herzog RW, Cao O, Srivastava A . Two decades of clinical gene therapy--success is finally mounting. Discov Med 2010; 9: 105–111.
Bouard D, Alazard-Dany D, Cosset FL . Viral vectors: from virology to transgene expression. Br J Pharmacol 2009; 157: 153–165.
Waehler R, Russell SJ, Curiel DT . Engineering targeted viral vectors for gene therapy. Nat Rev Genet 2007; 8: 573–587.
Navaratnarajah CK, Leonard VH, Cattaneo R . Measles virus glycoprotein complex assembly, receptor attachment, and cell entry. Curr Top Microbiol Immunol 2009; 329: 59–76.
Cattaneo R . Paramyxovirus entry and targeted vectors for cancer therapy. PLoS Pathog 2008; 6: e1000973.
Cattaneo R, Miest T, Shashkova EV, Barry MA . Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529–540.
Nakamura T, Peng KW, Vongpunsawad S, Harvey M, Mizuguchi H, Hayakawa T et al. Antibody-targeted cell fusion. Nat Biotechnol 2004; 22: 331–336.
Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23: 209–214.
Leonard VH, Sinn PL, Hodge G, Miest T, Devaux P, Oezguen N et al. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest 2008; 118: 2448–2458.
Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R . Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 2006; 66: 7694–7700.
Mühlebach MD, Schaser T, Zimmermann M, Armeanu S, Hanschmann KM, Cattaneo R et al. Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus. Cancer Res 2010; 70: 7620–7629.
Galanis E . Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther 2010; 88: 620–625.
Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R et al. Targeted cell entry of lentiviral vectors. Mol Ther 2008; 16: 1427–1436.
Frecha C, Costa C, Negre D, Gauthier E, Russell SJ, Cosset FL et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 2008; 112: 4843–4852.
Funke S, Schneider IC, Glaser S, Mühlebach MD, Moritz T, Cattaneo R et al. Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Therapy 2009; 16: 700–705.
Frecha C, Costa C, Levy C, Negre D, Russell SJ, Maisner A et al. Efficient and stable transduction of resting B lymphocytes and primary chronic lymphocyte leukemia cells using measles virus gp displaying lentiviral vectors. Blood 2009; 114: 3173–3180.
Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, Brynza J et al. Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 2010; 7: 929–935.
Matrai J, Chuah MK, VandenDriessche T . Recent advances in lentiviral vector development and applications. Mol Ther 2010; 18: 477–490.
Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818–823.
Miest TS, Yaiw KC, Frenzke M, Lampe J, Hudacek AW, Springfeld C et al. Envelope-chimeric entry-targeted Measles virus escapes neutralization and achieves oncolysis. Mol Ther 2011; 19: 1813–1820.
Springfeld C, von Messling V, Tidona CA, Darai G, Cattaneo R . Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism. J Virol 2005; 79: 10155–10163.
Jilani I, O’Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102: 3514–3520.
Bratt MA, Gallaher WR . Preliminary analysis of the requirements for fusion from within and fusion from without by Newcastle disease virus. Proc Natl Acad Sci USA 1969; 64: 536–543.
Buchholz CJ, Mühlebach MD, Cichutek K . Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer? Trends Biotechnol 2009; 27: 259–265.
Lamb RA, Parks GD . Paramyxoviridae: The Viruses and Their Replication. Fields Virology, 5th edn. Lippincott Williams & Wilkins: Philadelphia, 2007: 1449–1496.
Tidona CA, Kurz HW, Gelderblom HR, Darai G . Isolation and molecular characterization of a novel cytopathogenic paramyxovirus from tree shrews. Virology 1999; 258: 425–434.
von Messling V, Milosevic D, Devaux P, Cattaneo R . Canine distemper virus and measles virus fusion glycoprotein trimers: partial membrane-proximal ectodomain cleavage enhances function. J Virol 2004; 78: 7894–7903.
Kobayashi M, Iida A, Ueda Y, Hasegawa M . Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J Virol 2003; 77: 2607–2614.
Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, Pluckthun A, et al. DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther 2011; 19: 686–693.
Frecha C, Levy C, Cosset FL, Verhoeyen E . Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther 2010; 18: 1748–1757.
Frecha C, Levy C, Costa C, Negre D, Amirache F, Buckland R et al. Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J Virol 2011; 85: 5975–5985.
Zhou Q, Schneider IC, Gallet M, Kneissl S, Buchholz CJ . Resting lymphocyte transduction with measles virus glycoprotein pseudotyped lentiviral vectors relies on CD46 and SLAM. Virology 2011; 413: 149–152.
Bucheit AD, Kumar S, Grote DM, Lin Y, von Messling V, Cattaneo RB et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 2003; 7: 62–72.
Miyoshi H, Takahashi M, Gage FH, Verma IM . Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci USA 1997; 94: 10319–10323.
Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D . Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871–875.
Acknowledgements
This work was funded by a research grant (SP 694/5-1) from the German Research Foundation (DFG) to CS. We thank Roberto Cattaneo for providing the αHecto antibody and for continuous support.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Enkirch, T., Kneissl, S., Hoyler, B. et al. Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins. Gene Ther 20, 16–23 (2013). https://doi.org/10.1038/gt.2011.209
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2011.209